Robust isolation of malignant plasma cells in multiple myeloma.

Ildiko Frigyesi; Jörgen Adolfsson; Mina Ali; Mikael Kronborg Christophersen; Ellinor Johnsson; Ingemar Turesson; Urban Gullberg; Markus Hansson; Björn Nilsson

doi:10.1182/blood-2013-09-529800

Robust isolation of malignant plasma cells in multiple myeloma.

Ildiko Frigyesi, Jörgen Adolfsson, Mina Ali, Mikael Kronborg Christophersen, Ellinor Johnsson, Ingemar Turesson, Urban Gullberg, Markus Hansson, Björn Nilsson

Research output: Contribution to journal › Article › peer-review

Abstract

Molecular characterization of malignant plasma cells is increasingly important for diagnostic and therapeutic stratification in multiple myeloma (MM). However, the malignant plasma cells represent a relatively small subset of bone marrow cells, and need to be enriched prior to analysis. Currently, the cell surface marker CD138 (SDC1) is used for this enrichment, but has an important limitation in that its expression decreases rapidly after sampling. Seeking alternatives to CD138, we performed a computational screen for myeloma plasma cell markers and evaluated seven candidates systematically. Our results conclusively show that the markers CD319 (SLAMF7/CS1) and CD269 (TNFRSF17/BCMA) are considerably more robust than CD138, and enable isolation of myeloma plasma cells under more diverse conditions, including in samples that have been delayed or frozen. Our results form the basis of improved procedures for characterizing cases of multiple myeloma in clinical practice.

Original language	English
Pages (from-to)	1336-1340
Journal	Blood
Volume	123
Issue number	9
DOIs	https://doi.org/10.1182/blood-2013-09-529800
Publication status	Published - 2014

Bibliographical note

The information about affiliations in this record was updated in December 2015.
The record was previously connected to the following departments: Division of Clinical Genetics (013022003), Emergency medicine/Medicine/Surgery (013240200), Division of Hematology and Transfusion Medicine (013041100)

Subject classification (UKÄ)

Hematology

Access to Document

10.1182/blood-2013-09-529800

http://www.ncbi.nlm.nih.gov/pubmed/24385542?dopt=Abstract

1 Doctoral Thesis (compilation)

Identification and characterisation of SMIM1 variants determining the Vel blood group
Christophersen, M. K., 2017 Feb 22, Lund: Lund University: Faculty of Medicine. 94 p.
Research output: Thesis › Doctoral Thesis (compilation)

Open Access
File

1 Active

Genetic predisposition for multiple myeloma
Nilsson, B. (PI), Pertesi, M. (Researcher), Ajore, R. (Researcher), Wihlborg, A.-K. (Researcher), Duran Lozano, L. (Researcher), Cafaro, C. (Researcher), Johnsson, E. (Researcher), Hansson, M. (Researcher), Halvarsson, B.-M. (Researcher) & Niroula, A. (Researcher)
2011/01/03 → …
Project: Research

Cite this

@article{c3e71216e4d1436a8943862eed761439,

title = "Robust isolation of malignant plasma cells in multiple myeloma.",

abstract = "Molecular characterization of malignant plasma cells is increasingly important for diagnostic and therapeutic stratification in multiple myeloma (MM). However, the malignant plasma cells represent a relatively small subset of bone marrow cells, and need to be enriched prior to analysis. Currently, the cell surface marker CD138 (SDC1) is used for this enrichment, but has an important limitation in that its expression decreases rapidly after sampling. Seeking alternatives to CD138, we performed a computational screen for myeloma plasma cell markers and evaluated seven candidates systematically. Our results conclusively show that the markers CD319 (SLAMF7/CS1) and CD269 (TNFRSF17/BCMA) are considerably more robust than CD138, and enable isolation of myeloma plasma cells under more diverse conditions, including in samples that have been delayed or frozen. Our results form the basis of improved procedures for characterizing cases of multiple myeloma in clinical practice.",

author = "Ildiko Frigyesi and J{\"o}rgen Adolfsson and Mina Ali and Christophersen, {Mikael Kronborg} and Ellinor Johnsson and Ingemar Turesson and Urban Gullberg and Markus Hansson and Bj{\"o}rn Nilsson",

note = "The information about affiliations in this record was updated in December 2015. The record was previously connected to the following departments: Division of Clinical Genetics (013022003), Emergency medicine/Medicine/Surgery (013240200), Division of Hematology and Transfusion Medicine (013041100)",

year = "2014",

doi = "10.1182/blood-2013-09-529800",

language = "English",

volume = "123",

pages = "1336--1340",

journal = "Blood",

issn = "1528-0020",

publisher = "American Society of Hematology",

number = "9",

}

TY - JOUR

T1 - Robust isolation of malignant plasma cells in multiple myeloma.

AU - Frigyesi, Ildiko

AU - Adolfsson, Jörgen

AU - Ali, Mina

AU - Christophersen, Mikael Kronborg

AU - Johnsson, Ellinor

AU - Turesson, Ingemar

AU - Gullberg, Urban

AU - Hansson, Markus

AU - Nilsson, Björn

N1 - The information about affiliations in this record was updated in December 2015. The record was previously connected to the following departments: Division of Clinical Genetics (013022003), Emergency medicine/Medicine/Surgery (013240200), Division of Hematology and Transfusion Medicine (013041100)

PY - 2014

Y1 - 2014

N2 - Molecular characterization of malignant plasma cells is increasingly important for diagnostic and therapeutic stratification in multiple myeloma (MM). However, the malignant plasma cells represent a relatively small subset of bone marrow cells, and need to be enriched prior to analysis. Currently, the cell surface marker CD138 (SDC1) is used for this enrichment, but has an important limitation in that its expression decreases rapidly after sampling. Seeking alternatives to CD138, we performed a computational screen for myeloma plasma cell markers and evaluated seven candidates systematically. Our results conclusively show that the markers CD319 (SLAMF7/CS1) and CD269 (TNFRSF17/BCMA) are considerably more robust than CD138, and enable isolation of myeloma plasma cells under more diverse conditions, including in samples that have been delayed or frozen. Our results form the basis of improved procedures for characterizing cases of multiple myeloma in clinical practice.

AB - Molecular characterization of malignant plasma cells is increasingly important for diagnostic and therapeutic stratification in multiple myeloma (MM). However, the malignant plasma cells represent a relatively small subset of bone marrow cells, and need to be enriched prior to analysis. Currently, the cell surface marker CD138 (SDC1) is used for this enrichment, but has an important limitation in that its expression decreases rapidly after sampling. Seeking alternatives to CD138, we performed a computational screen for myeloma plasma cell markers and evaluated seven candidates systematically. Our results conclusively show that the markers CD319 (SLAMF7/CS1) and CD269 (TNFRSF17/BCMA) are considerably more robust than CD138, and enable isolation of myeloma plasma cells under more diverse conditions, including in samples that have been delayed or frozen. Our results form the basis of improved procedures for characterizing cases of multiple myeloma in clinical practice.

U2 - 10.1182/blood-2013-09-529800

DO - 10.1182/blood-2013-09-529800

M3 - Article

C2 - 24385542

SN - 1528-0020

VL - 123

SP - 1336

EP - 1340

JO - Blood

JF - Blood

IS - 9

ER -

Robust isolation of malignant plasma cells in multiple myeloma.

Abstract

Bibliographical note

Subject classification (UKÄ)

Access to Document

Fingerprint

Research output

Identification and characterisation of SMIM1 variants determining the Vel blood group

Projects

Genetic predisposition for multiple myeloma

Cite this